Document Detail

The hematopoietic effect of Epotin (recombinant human erythropoietin-alpha) on maintenance hemodialysis end-stage kidney disease patients.
MedLine Citation:
PMID:  20430164     Owner:  NLM     Status:  MEDLINE    
Recombinant human erythropoietin (rHuEpo) has revolutionized the management of renal anemia, significantly improving patient quality of life. Great attention has been paid lately on how to optimally use this potent anti-anemic agent. Aiming to overview anemic patient management with Epotin (Julphar's rHuEpo) according to the new guidelines, we included in the study anemic (hemoglobin [Hb]<or=11 g/dL) end-stage kidney disease (ESKD) patients (n=35) of ages>or=18 years who were of iron replete (transeferene saturation (TSAT)>or=20% and serum ferritin>or=100 microg/L) with no evidence of serious inflammation (c-reactive protein (CRP)<30 mg/L) on thrice-weekly hemodialysis. The mean age and dialysis duration of 50.8+/-17 and 3.8+/-2.8 years, respectively, included 88.6% (n=31) de novo patients in the corrective phase with no previous exposure to erythropoietin. Safety-efficacy parameters showed insignificant changes throughout the 4-month study period, including iron profile that was maintained according to Kidney Disease Outcome Quality Initiative guidelines. Efficacy parameters revealed a significant increase (P<.0001) of Hb levels from a baseline of 8.5+/-1.0 to 11.1+/-1.1. Targeting an absolute increase of 2.5 g/dL in Hb throughout 3 months of the study period resulted in a 90.3% success rate. There were no dropouts due to intolerance, whereas all the recorded adverse events were classified as unrelated to the test product. In conclusion, Epotin was clinically effective to correct and maintain Hb levels in ESKD anemic patients on maintenance hemodialysis within the current recommended range and with a satisfactory safety profile consistent with previous international reports.
S Al-Shohaib; D S Shaker; B B Ghaedi; M Alyarim; S Emara; M Behairy
Related Documents :
20472854 - Diagnosis of iron deficiency in patients undergoing hemodialysis.
3122564 - A mild uncompensated alkalosis in anemia.
16843874 - Preoperative nutritional status of patients undergoing roux-en-y gastric bypass for mor...
15965214 - Restless legs syndrome and low brain iron levels in patients with haemochromatosis.
23471614 - Cerebrospinal fluid biomarkers in patients with varicella-zoster virus cns infections.
19226274 - Chemokine cc-ligand 5 production and eosinophil activation into the upper airways of as...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation proceedings     Volume:  42     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-30     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  753-9     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 Elsevier Inc. All rights reserved.
College of Medicine and King Abdul Aziz University Hospital/Kingdom of Saudi Arabia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia / drug therapy,  etiology
Combined Modality Therapy
Epoetin Alfa / therapeutic use*
Erythropoiesis / drug effects*
Hematinics / therapeutic use*
Hemoglobins / drug effects,  metabolism
Kidney Failure, Chronic / complications,  drug therapy*
Renal Dialysis
Reg. No./Substance:
0/Hematinics; 0/Hemoglobins; 113427-24-0/Epoetin Alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ischemia and Reperfusion of the Lung Tissues Induced Increase of Lung Permeability and Lung Edema Is...
Next Document:  Effect of pretransplantation hemoglobin blood concentration on renal allograft survival and function...